-----------------------------------------------------------------------
NET INCOME $1,229 $965 27%
=======================================================================
BASIC EPS $1.90 $1.49 28%
=======================================================================
DILUTED EPS $1.87 $1.47 27%
=======================================================================
WEIGHTED AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING
Basic 647 650
Diluted 657 656
-----------------------------------------------------------------------
ADJUSTED PRE-TAX INCOME
(excluding certain items) $1,681(6) $1,307(6) 29%
ADJUSTED NET INCOME
(excluding certain items) $1,338(6) $1,029(6) 30%
ADJUSTED DILUTED EPS
(excluding certain items) $2.03(6) $1.57(6) 29%
(1) Cost of goods sold in 2006 included a $76 million pre-tax charge
($64 million, or $0.10 per share, on an after-tax basis) related to
COLLEAGUE infusion pumps.
(2) Marketing and administrative expenses in 2007 included a pre-tax
charge of $56 million ($34 million, or $0.05 per diluted share, on an
after-tax basis) related to the company's AWP litigation.
(3) Research and development expenses in 2007 included IPR&D charges of
$25 million related to the company's collaboration for the
development of a next-generation home hemodialysis machine, and
$10 million related to the company's in-licensing arrangement with
Halozyme Therapeutics, Inc. The after-tax impact of t
'/>"/>
| SOURCE Baxter International Inc. Copyright©2007 PR Newswire. All rights reserved |